- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neumora Therapeutics Inc (NMRA)Neumora Therapeutics Inc stock price live, this page displays NASDAQ NMRA stock exchange data. View the NMRA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neumora Therapeutics Inc real time stock price chart below.
What Is the Neumora Therapeutics Inc Stock Price Today?
The Neumora Therapeutics Inc stock price today is 9.80.
What Is the Stock Symbol for Neumora Therapeutics Inc?
The stock ticker symbol for Neumora Therapeutics Inc is NMRA.
Is NMRA the Same as $NMRA?
$NMRA is a common way to refer to the Neumora Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Neumora Therapeutics Inc Trade On?
Neumora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neumora Therapeutics Inc a Good Stock to Buy?
Determining whether Neumora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Neumora Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMRA quote. (ISIN: US6409791000)
What Is the Neumora Therapeutics Inc Stock Price Today?
The Neumora Therapeutics Inc stock price today is 9.80.
What Is the Stock Symbol for Neumora Therapeutics Inc?
The stock ticker symbol for Neumora Therapeutics Inc is NMRA.
Is NMRA the Same as $NMRA?
$NMRA is a common way to refer to the Neumora Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Neumora Therapeutics Inc Trade On?
Neumora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neumora Therapeutics Inc a Good Stock to Buy?
Determining whether Neumora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Neumora Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMRA quote. (ISIN: US6409791000)
NASDAQ
Currency in USD
9.80
-0.14(-1.41%)
Closed
After Hours
9.800.00(0.00%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.63
10.02
52 wk Range
8.33
21.00
NMRA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.6310.02
52 wk Range
8.3321.00
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockNMRA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
23.33
Upside
+138.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Neumora Therapeutics Inc Company Profile
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Neumora Therapeutics Inc SWOT Analysis
Analyst Outlook | Consensus price target of $29.00 reflects optimism about Neumora's prospects, with analysts rating the stock "Outperform" despite speculative risks |
Competitive Edge | Delve into Neumora's strategic positioning against competitors like Johnson & Johnson, and the potential advantages of navacaprant in the MDD market |
Market Potential | Navacaprant's market opportunity in MDD treatment is estimated at $2-2.8 billion, highlighting significant growth potential for Neumora Therapeutics |
MDD Trial Progress | Explore Neumora's Phase III KOASTAL-1 trial for navacaprant, a promising KOR antagonist for major depressive disorder, with readout expected in Q4 2024 |
Compare NMRA to Peers and Sector
Metrics to compare | NMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.4x | −1.8x | −0.7x | |
PEG Ratio | −0.09 | −0.01 | 0.00 | |
Price / Book | 4.9x | 1.2x | 2.6x | |
Price / LTM Sales | - | 1.9x | 3.2x | |
Upside (Analyst Target) | 131.4% | 133.3% | 43.2% | |
Fair Value Upside | Unlock | 17.4% | 6.8% | Unlock |
Analysts' Recommendations
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 23.33
(+138.02% Upside)
People Also Watch
FAQ
What Is the Neumora Therapeutics (NMRA) Stock Price Today?
The Neumora Therapeutics stock price today is 9.80
What Stock Exchange Does Neumora Therapeutics Trade On?
Neumora Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Neumora Therapeutics?
The stock symbol for Neumora Therapeutics is "NMRA."
What Is the Neumora Therapeutics Market Cap?
As of today, Neumora Therapeutics market cap is 1.61B.
What is Neumora Therapeutics Earnings Per Share?
The Neumora Therapeutics EPS is -1.86.
From a Technical Analysis Perspective, Is NMRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.